Our results from the PD-L1 experiments not only support the role of weakened immune checkpoint regulation in the more severe arthritis in NOX2-deficient conditions, but also showed that replenishment of PD-L1 may be a potential therapeutic approach in some patients with immune-mediated arthritis. The gene discussed is CD274; the disease is Arthritis.